|
Female, %
|
36
|
60
|
52
|
53
|
47
|
58
|
|
Age at index, years, median (range)
|
46.5 (18–75)
|
33.0 (19–76)
|
35.0 (20–66)
|
41.0 (22–60)
|
39.5 (18–75)
|
34.0 (19–76)
|
|
UC duration, years, median (range) [n with available data]a
|
5.8 (0–29) [21]
|
4.2 (0–33) [40]
|
6.7 (1–47) [54]
|
6.7 (2–41) [17]
|
6.1 (0–47) [75]
|
4.7 (0–41) [57]
|
|
UC location, [n]
|
[21]
|
[35]
|
[45]
|
[12]
|
[66]
|
[47]
|
|
Ulcerative proctitis, %
|
0
|
9
|
9
|
8
|
6
|
9
|
|
Left-sided, %
|
29
|
40
|
29
|
42
|
29
|
40
|
|
Extensive colitis, %
|
10
|
11
|
9
|
17
|
9
|
13
|
|
Pancolitis, %
|
62
|
40
|
53
|
33
|
56
|
38
|
|
Prior IBD-related surgery, %
|
5
|
5
|
2
|
0
|
3
|
4
|
|
Total Mayo score, mean (SD) [n]
|
5.9 (3.2) [10]
|
5.7 (2.7) [16]
|
6.1 (2.8) [27]
|
7.7 (3.0) [6]
|
6.0 (2.9) [37]
|
6.2 (2.9) [22]
|
|
Partial Mayo score, mean (SD) [n]
|
4.8 (2.7) [12]
|
4.8 (2.5) [18]
|
4.9 (2.5) [35]
|
6.9 (2.1) [7]
|
4.9 (2.6) [47]
|
5.4 (2.5) [25]
|
|
Rectal bleeding score, [n]
|
[14]
|
[26]
|
[44]
|
[12]
|
[58]
|
[38]
|
|
0 (no blood seen), %
|
36
|
38
|
41
|
25
|
40
|
34
|
|
1 (streaks of blood with stool < half of time), %
|
36
|
23
|
30
|
17
|
31
|
21
|
|
2 (obvious blood with stool most of the time), %
|
14
|
27
|
23
|
25
|
21
|
26
|
|
3 (blood alone passes), %
|
14
|
12
|
7
|
33
|
9
|
18
|
|
Stool frequency score, [n]
|
[15]
|
[23]
|
[48]
|
[11]
|
[63]
|
[34]
|
|
0 (normal number of stools), %
|
7
|
4
|
17
|
0
|
14
|
3
|
|
1 (1–2 stools/day more than normal), %
|
33
|
22
|
8
|
0
|
14
|
15
|
|
2 (3–4 stools/day more than normal), %
|
13
|
22
|
19
|
9
|
17
|
18
|
|
3 (≥5 stools/day more than normal), %
|
47
|
52
|
56
|
91
|
54
|
65
|
|
Endoscopic score, [n]
|
[12]
|
[20]
|
[27]
|
[8]
|
[39]
|
[28]
|
|
0 (normal or inactive disease), %
|
25
|
30
|
11
|
38
|
15
|
32
|
|
1 (mild disease), %
|
33
|
35
|
19
|
13
|
23
|
29
|
|
2 (moderate disease), %
|
25
|
25
|
48
|
25
|
41
|
25
|
|
3 (severe disease), %
|
17
|
10
|
22
|
25
|
21
|
14
|
|
Corticosteroids in past 2 years, %
|
73
|
68
|
78
|
76
|
76
|
70
|
|
Aminosalicylates in past 2 years, %
|
86
|
70
|
78
|
71
|
80
|
70
|
|
Immunomodulators in past 2 years, %
|
55
|
58
|
43
|
59
|
46
|
58
|
|
Duration of previous anti-TNFα treatment, months, mean (SD), [n]
|
–
|
–
|
16.8 (16.9) [47]
|
19.5 (17.0) [16]
|
16.8 (16.9) [47]
|
19.5 (17.0) [16]
|
|
Duration from prior anti-TNFα discontinuation to index date, months, median (range), [n]
|
–
|
–
|
1.4 (0–32) [50]
|
1.2 (0–44) [17]
|
1.4 (0–32) [50]
|
1.2 (0–44) [17]
|
|
Index treatment, anti-TNFα type
|
|
Infliximab originator, %
|
–
|
55
|
–
|
18
|
–
|
44
|
|
Infliximab biosimilar, %
|
–
|
15
|
–
|
0
|
–
|
11
|
|
Adalimumab, %
|
–
|
15
|
–
|
35
|
–
|
21
|
|
Golimumab, %
|
–
|
15
|
–
|
47
|
–
|
25
|
|
Concomitant therapy at index
|
|
Corticosteroids, %
|
41
|
50
|
44
|
41
|
43
|
47
|
|
Immunomodulators, %
|
23
|
28
|
20
|
35
|
21
|
30
|
|
Aminosalicylates, %
|
59
|
50
|
56
|
53
|
57
|
51
|
